For restricted or no oral intake. ANDA 206687, held by Fresenius Kabi USA. Sodium Acetate.
As of Nov 15, 2026, ANDA 206687 (Sodium Acetate), held by Fresenius Kabi USA, was first approved by FDA on Oct 30, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Sodium Acetate Injection, USP (4 mEq per mL) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Acetate400MEQ/100ML (4MEQ/ML) · solution;intravenous | Sodium Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters